In line with our commitment to improving women's health by providing a full line of advanced diagnostics, Hologic offers the Aptima HPV 16 18/45 genotype assay.
The first Health Canada and FDA-approved test for genotyping human papillomavirus (HPV) types 16, 18 and/or 45 from women with Aptima HPV assay positive results.
Recent data suggests that while the incidence of cervical cancer has decreased since the 1970s, the prevalence of adenocarcinoma cases has risen approximately 32% in the same time frame.1
A rising trend
HPV genotype 45 is fairly uncommon, identified in only 0.4% of women with normal cytology. Yet data indicates that it is the third most common HPV genotype in invasive cancer. Testing for HPV genotype 45 is designed to help identify more women at risk for adenocarcinoma, with minimal impact to colposcopy rates. Making the identification of these types part of reflex testing may pinpoint up to 94% of all cervical adenocarcinomas.2
Aptima HPV 16 18/45 genotype assay from Hologic — next generation technology, today.
HPV genotypes in invasive cervical cancer2
The Aptima HPV 16 18/45 genotype assay is FDA-approved in the U.S. for in vitro diagnostic use on the Panther and Tigris systems. The Aptima HPV 16 18/45 genotype assay was CE-marked in December 2011.
For additional availability in other countries beyond the U.S., please contact your local sales representative or distributor.
